Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003

Increased national disease awareness benefited in vitro diagnostic developers in 2003, as new U.S. testing guidelines and the SARS epidemic, as well as recovery in the broader U.S. economy, helped fuel stock growth